Recent Updates
Recently added Catalysts

MK0594

Phase 2

Urinary Incontinence | Small molecule | Nephrology |VYNE Therapeutics Inc.|Last Updated: May 19, 2021

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment557
FDA Designations
No designations recorded
Clinical trial landscape

MK0594 · 1 trial · 2 indications

Phase 2 1
NCT00290563Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)Urinary Incontinence
COMPLETED557 Analytics
PHASE2COMPLETED
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
Urinary Incontinence
NCT00290563557
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change in baseline in average daily micturitions as recorded on patient voiding diaries.
Duration of Trial
Secondary Endpoints
The incidence of dry mouth.
Duration of Treatment
Average daily strong urgency, total incontinence, and Urge UI episodes from voiding diaries.
Duration of Treatment
Global assessment of improvement in UI, perception of urgency, and bother of UI symptoms.
Duration of Treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0594DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years to 74 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients with predominantly urge incontinence overactive bladder episodes * Patients must meet minimum eligibility requirements (e.g., average number of micturitions/day) based on screening diary cards Exclusion Criteria: * History of Diabetes insipidus, uncontrolled hypergl...

Unlock Eligibility Criteria